Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma

被引：1

作者：

Shiraishi, Kazuhiro ^{[1
]}

Takeyasu, Yuki ^{[1
,3
]}

Yamamoto, Shun ^{[1
,2
]}

Oshima, Kotoe ^{[2
]}

Imazeki, Hiroshi ^{[1
]}

Hirano, Hidekazu ^{[2
]}

Okita, Natsuko ^{[2
]}

Shoji, Hirokazu ^{[2
]}

Honma, Yoshitaka ^{[1
,2
]}

Iwasa, Satoru ^{[2
]}

Takasima, Atsuo ^{[2
]}

Kato, Ken ^{[1
,2
]}

机构：

[1] Natl Canc Ctr, Dept Head & Neck Esophageal Med Oncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

[2] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

[3] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, Japan

来源：

ESOPHAGUS | 2024年 / 21卷 / 04期

关键词：

Esophageal squamous cell carcinoma; PD-1; blockade; Immune checkpoint inhibitor; Chemotherapy; Taxane; PHASE-II EVALUATION; SALVAGE CHEMOTHERAPY; CANCER; VEMURAFENIB; 5-FLUOROURACIL; COMBINATION; PROGRESSION; INHIBITORS; CISPLATIN; INFUSION;

D O I：

10.1007/s10388-024-01085-5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BackgroundProgrammed cell death-1 (PD-1) blockade improves survival in patients with advanced esophageal squamous cell carcinoma (ESCC). However, the efficacy of taxanes after exposure to PD-1 blockade remains unclear in patients with advanced ESCC.MethodsWe retrospectively analyzed the clinical outcomes of advanced ESCC patients treated with taxanes (paclitaxel or docetaxel) with/without prior exposure to PD-1 blockade (Exposed /Na & iuml;ve group) at National Cancer Center Hospital from June 2016 to December 2020.ResultsNinety-nine patients (Exposed group, n = 32; Na & iuml;ve group, n = 67) were included. The objective response rate (ORR) of the Exposed group was significantly higher than that of the Na & iuml;ve group (37.5% vs. 13.4%, p = 0.009). The median progression-free survival was similar between the Exposed and Na & iuml;ve groups (3.8 vs. 2.8 months, HR 1.12, 95% CI 0.65-1.86, p = 0.66). PD-1 blockade exposure independently predicated higher ORR to taxanes in multivariate analysis. Grade >= 3 adverse events were comparable between the Exposed and Na & iuml;ve groups (45.8% vs. 40.3%, p = 0.64).ConclusionsTaxanes following PD-1 blockade in advanced ESCC showed a higher ORR but similar PFS compared to taxanes without prior PD-1 exposure.

引用

页码：539 / 545

页数：7

共 24 条

[1] Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS) [J].

Adenis, A. ;

Bennouna, J. ;

Etienne, P. L. ;

Bogart, E. ;

Francois, E. ;

Galais, M. P. ;

Ben Abdelghani, M. ;

Michel, P. ;

Metges, J. P. ;

Dahan, L. ;

Conroy, T. ;

Ghiringhelli, F. ;

Drouillard, A. ;

El Hajbi, F. ;

Samalin, E. ;

Hiret, S. ;

Delaine-Clisant, S. ;

Mariette, C. ;

Penel, N. ;

Piessen, G. ;

Le Deley, M. C. .

EUROPEAN JOURNAL OF CANCER, 2019, 111 :12-20

[2] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[3] Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3 [J].

Chin, Keisho ;

Yamamoto, Shun ;

Takahashi, Masanobu ;

Kadowaki, Shigenori ;

Kubota, Yutaro ;

Amanuma, Yusuke ;

Okada, Morihito ;

Kanda, Mitsuro ;

Kimura, Yasue ;

Nogi, Yuhiko ;

Arimitsu, Yuko ;

Kitagawa, Yuko .

ESOPHAGUS, 2023, 20 (02) :302-308

[4] Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma [J].

Doki, Y. ;

Ajani, J. A. ;

Kato, K. ;

Xu, J. ;

Wyrwicz, L. ;

Motoyama, S. ;

Ogata, T. ;

Kawakami, H. ;

Hsu, C. -H. ;

Adenis, A. ;

El Hajbi, F. ;

Di Bartolomeo, M. ;

Braghiroli, M. I. ;

Holtved, E. ;

Ostoich, S. A. ;

Kim, H. R. ;

Ueno, M. ;

Mansoor, W. ;

Yang, W. -C. ;

Liu, T. ;

Bridgewater, J. ;

Makino, T. ;

Xynos, I. ;

Liu, X. ;

Lei, M. ;

Kondo, K. ;

Patel, A. ;

Gricar, J. ;

Chau, I. ;

Kitagawa, Y. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05) :449-462

[5] The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies [J].

Emens, Leisha A. ;

Middleton, Gary .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (05) :436-443

[6] Vemurafenib Sensitivity Skin Reaction after Ipilimumab [J].

Harding, James J. ;

Pulitzer, Melissa ;

Chapman, Paul B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :866-868

[7] Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407) [J].

Hayashi, K ;

Ando, N ;

Watanabe, H ;

Ide, H ;

Nagai, K ;

Aoyama, N ;

Takiyama, W ;

Ishida, K ;

Isono, K ;

Makuuchi, H ;

Imamura, M ;

Shinoda, M ;

Ikeuchi, S ;

Kabuto, T ;

Yamana, H ;

Fukuda, H .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (09) :419-423

[8] A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma [J].

Hiramoto, Shuji ;

Kato, Ken ;

Shoji, Hirokazu ;

Okita, Natsuko ;

Takashima, Atsuo ;

Honma, Yoshitaka ;

Iwasa, Satoru ;

Hamaguchi, Tetsuya ;

Yamada, Yasuhide ;

Shimada, Yasuhiro ;

Boku, Narikazu .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) :466-472

[9]

IIZUKA T, 1992, JPN J CLIN ONCOL, V22, P172

[10] Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy [J].

Johnson, Douglas B. ;

Wallender, Erika K. ;

Cohen, Daniel N. ;

Likhari, Sunaina S. ;

Zwerner, Jeffrey P. ;

Powers, Jennifer G. ;

Shinn, Lisa ;

Kelley, Mark C. ;

Joseph, Richard W. ;

Sosman, Jeffrey A. .

CANCER IMMUNOLOGY RESEARCH, 2013, 1 (06) :373-377

← 1 2 3 →